| Literature DB >> 26235614 |
Anna Kuchnio1, Stijn Moens1, Ulrike Bruning1, Karol Kuchnio1, Bert Cruys1, Bernard Thienpont2, Michaël Broux1, Andreea Alexandra Ungureanu3, Rodrigo Leite de Oliveira4, Françoise Bruyère1, Henar Cuervo1, Ann Manderveld1, An Carton1, Juan Ramon Hernandez-Fernaud5, Sara Zanivan5, Carmen Bartic6, Jean-Michel Foidart7, Agnes Noel7, Stefan Vinckier1, Diether Lambrechts2, Mieke Dewerchin1, Massimiliano Mazzone8, Peter Carmeliet9.
Abstract
Several questions about the role of the oxygen sensor prolyl-hydroxylase 2 (PHD2) in cancer have not been addressed. First, the role of PHD2 in metastasis has not been studied in a spontaneous tumor model. Here, we show that global PHD2 haplodeficiency reduced metastasis without affecting tumor growth. Second, it is unknown whether PHD2 regulates cancer by affecting cancer-associated fibroblasts (CAFs). We show that PHD2 haplodeficiency reduced metastasis via two mechanisms: (1) by decreasing CAF activation, matrix production, and contraction by CAFs, an effect that surprisingly relied on PHD2 deletion in cancer cells, but not in CAFs; and (2) by improving tumor vessel normalization. Third, the effect of concomitant PHD2 inhibition in malignant and stromal cells (mimicking PHD2 inhibitor treatment) is unknown. We show that global PHD2 haplodeficiency, induced not only before but also after tumor onset, impaired metastasis. These findings warrant investigation of PHD2's therapeutic potential.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26235614 DOI: 10.1016/j.celrep.2015.07.010
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423